Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone app aims to boost breast cancer treatment adherence

NCT ID NCT04554927

Disease control Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a web application can help breast cancer patients take their hormone therapy as prescribed. About 438 patients starting hormone therapy will either use the app or receive standard care. The goal is to see if the app improves medication adherence and quality of life over 18 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
web application
What this could lead to
If it works, this could show that a simple web app helps breast cancer patients take their hormone therapy more consistently, potentially improving treatment outcomes.
What could go wrong
This is a relatively small, single-center trial testing a behavioral intervention, not a new drug. The app may not significantly improve adherence, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 438 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient \> 18 years old * Breast cancer patient candidate for adjuvant hormone therapy * Mastery of the French language * Patient with a cell phone and an Internet connection * Patient able to use a computer, smartphone, or tablet. * Patient affiliated to a social security system * Signing of informed consent prior to any specific study-related procedure Exclusion Criteria: * Patient who has previously received hormone therapy for cancer. * Patient not trained in the use of the application * Any associated medical or psychiatric condition that might compromise the patient's ability to participate in the study * Patients with locoregional or metastatic recurrence * Other history of cancer. * Patient deprived of liberty, under guardianship or curatorship * Simultaneous participation in a therapeutic clinical trial or other clinical study involving a connected tool * Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Hormono therapy Web-application

Contacts and locations

Locations

  • Centre François baclesse

    Caen, 14000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.